Company intelligence / Profile preview

Lingraphica

Princeton, New Jersey, United Stateslingraphica.com ↗

Ownership: Private
Employees: ~169
Development stage: Commercial

Overview

Lingraphica’s AAC devices and therapy apps are commercially available and widely used by adults with aphasia, dysarthria, verbal apraxia, and other speech/language disorders. Their products are covered by Medicare/Medicaid/commercial insurance in the US. The company has contributed to research showing that people with aphasia can continue to improve communication skills beyond traditional recovery windows.

Therapeutic areas: Neurology
Modalities: Device (specifically Augmentative and Alternative Communication (AAC) devices)Software (therapy apps)Non-pharmacological therapy
Industry: Assistive Medical Devices

Partnerships

Collaborates with clinicians/caregivers; no major pharma/biotech partnerships identified.

Beyond the preview

Go deeper on Lingraphica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lingraphica.

Explore the full profile